Proteomics International Laboratories Successfully Closes IPO

Emerging life science company Proteomics International Laboratories Ltd (proposed ASX: PIQ) is pleased to announce that it has successfully closed its new IPO after raising $3.1 million amidst strong investor demand.

The Company is delighted with the strong level of investor interest in the Offer, and expects to commence trading on the ASX in the near future under the ASX code: PIQ.

PIQ is a specialist technology-driven life sciences company focused on the area of proteomics, the industrial scale study of proteins. It was founded in 2001 and is an established, revenue generating business, recognised as a global leader in its field.

The Company’s business model is based on its proprietary technology platform which operates across three synergistic business units in massive growth markets:

1. Analytical services – Specialist contract research, analytical testing and consultancy – fee for service model. The proteomics market is estimated to be worth $20.8bn by 2018.
2. Diagnostics – Biomarkers of diseases and personalised medicine – focus on diabetic kidney disease and Alzheimer’s disease. The biomarkers market is estimated to be worth $40.8bn by 2018.
3. Therapeutics – Peptide drug discovery with a focus on painkillers and antibiotics. The peptide therapeutics market is currently estimated to be worth $17bn.

The proceeds of the IPO will be used to expand and accelerate the growth of each business unit.

The Company has a substantial portfolio of clients and partners, including: CSIRO, Reliance Life Sciences, inVentive Health Clinical, Australian National University, National University of Singapore and Royal Institute of Technology (Sweden).

PIQ has a global standing in its field. The Company was the first in the world to receive ISO 17025 laboratory accreditation for proteomics services, and its team operates from state-of- the art facilities at the Harry Perkins Institute of Medical Research in Perth, Western Australia.

The Company has a highly credentialed board, which includes: Managing Director and co- founder Dr Richard Lipscombe, a highly experienced and successful business manager and protein chemist; Chairman Terry Sweet, a scientific-technology company director and executive with 30 years experience (see Board profiles attached). The Financial Adviser and Lead Manager to the Offer is Sydney-based corporate advisory
firm K S Capital.

To download the full document, please click on the link below.